Clinical Trial

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

Suspended Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity.
Summary
This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).
Protocol Amendment History 4 changes
critical Recruitment suspended 2026-07-30
critical Recruitment suspended: The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any... 2026-07-30
minor Completion pushed: 2028-08-07 -> 2029-05-11 2026-07-30
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07547436
Lead Sponsor Sanofi
Conditions Non-cystic Fibrosis Bronchiectasis
Enrollment 70 participants
Start Date 2026-06-08
Primary Completion 2027-10-29 (estimated)
Study Completion 2029-05-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-29